Stoke Therapeutics, Inc.
STOK • NASDAQ
Stoke Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Ian F. Smith, with a market cap of $2.2B.
CEOIan F. Smith
Next Earnings
Upcoming earnings announcement for Stoke Therapeutics, Inc.
Date
Tuesday, May 12, 2026 (in 2 months)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.76
Revenue Estimate
$7.5M
Earnings History
Past 11 earnings reports for Stoke Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | Q3 2025 | -$0.65Est: -$0.58 | -12.1% | $10.6MEst: $6.0M | +76.1% |  10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.40Est: -$0.55 | +27.3% | $13.8MEst: $5.1M | +170.6% | 10-Q |
| May 13, 2025 | Q1 2025 | $1.90Est: -$0.61 | +411.5% | $158.6MEst: $2.8M | +5503.1% | 10-Q |
| Mar 18, 2025 | Q4 2024 | -$0.18Est: -$0.54 | +66.7% | $22.6MEst: $4.2M | +438.4% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$0.47Est: -$0.53 | +11.3% | $4.9MEst: $3.4M | +46.1% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.46Est: -$0.55 | +16.4% | $4.8MEst: $3.4M | +41.7% | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.57Est: -$0.61 | +6.6% | $4.2MEst: $3.2M | +31.3% | 10-Q |
| Mar 25, 2024 | Q4 2023 | -$0.60Est: -$0.63 | +4.8% | $2.8MEst: $3.3M | -13.8% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.55Est: -$0.63 | +12.7% | $3.3MEst: $3.2M | +3.7% | — |
| Aug 7, 2023 | Q2 2023 | -$0.69Est: -$0.64 | -7.8% | -$2.5MEst: $3.4M | -172.1% | 10-Q |
| May 4, 2023 | Q1 2023 | -$0.53Est: -$0.69 | +23.2% | $5.5MEst: $3.0M | +83.7% | — |